iVisitDoc is a telehealth company that provides medical services online, focusing on areas such as weight loss therapies. It offers a seamless, user-friendly platform for people unfamiliar with telemedicine, allowing them to access healthcare services remotely and providing solutions for over 175,000 patients across the U.S. One of its key features includes transformative weight loss therapies, such as Compounded Semaglutide and Tirzepatide, with subscription plans tailored to users’ needs.

iVisitDoc is not intended to replace your primary care physician but to enhance that relationship. For instance, it's estimated that 70% of physician visits can be managed via phone. However, there are situations where we may recommend seeing your primary care physician in person or assist you in finding one if you don't already have a relationship.

Yes, iVisitDoc is a subscription service. We offer physician consultations as needed, with no monthly or annual fees.

Lab test results are securely delivered to your iVisitDoc account. You'll receive a notification when they are ready, and you can access them through your patient portal.

Yes. If the iVisitDoc physician finds it necessary, they can prescribe medications during your virtual consultation. The prescription will be sent directly to your preferred pharmacy.

You can schedule a follow-up appointment through your iVisitDoc account. Simply log in and go to the appointments section to select a convenient time for your next consultation.

It's important to inform your iVisitDoc physician about any known allergies during your consultation. They will review your medical history and prescribe medications that are safe and appropriate for your condition.

At iVisitDoc, we simplify healthcare with transparent pricing. No insurance required – your medical visit, ongoing treatment shipments, and provider messaging are all included in one affordable price. Experience convenient, high-quality care without the hassle of hidden fees or complicated coverage.

Semaglutide is a medication that belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists.

It mimics the GLP-1 hormone, which is naturally released in the gastrointestinal tract after eating.

Semaglutide is mainly used to treat type 2 diabetes and is also approved for weight management in people who are overweight or obese. It comes in different forms, including injections and oral tablets.

Yes and No. Oral semaglutide is only for managing type 2 diabetes, but other forms can be used for weight management without needing diabetes. To qualify for weight management, doctors typically check factors like your BMI and waist circumference.

The doctor won’t rely solely on BMI, but it is part of the screening process. Candidates for semaglutide therapy include individuals who haven’t achieved at least 5% weight loss after 3-6 months of lifestyle changes and either have obesity with a BMI of 30 or higher, or a BMI between 27-29.9 with at least one weight-related condition. Waist circumference is also checked to confirm excess fat, distinguishing it from a high BMI due to muscle mass.

Obesity is determined by an elevated BMI (body mass index), which is calculated using a person’s weight and height, along with an increase in waist circumference. A BMI below 25 is considered normal, 25-29.99 is overweight, 30 or higher is obese, and over 40 is classified as morbid obesity. For Asian individuals, overweight starts at a BMI of 23-24.9, and obesity is defined as a BMI over 25. Obesity significantly increases the risk of health conditions like diabetes, hypertension, heart disease, and cancer, while weight loss reduces these risks.

Tirzepatide is a dual-action medication that acts as a GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, demonstrating significant effectiveness in promoting weight loss in individuals who are overweight or obese.

Consulting with a doctor is the best way to determine what’s right for you. However, tirzepatide may be more effective than semaglutide because it is a dual-action GLP-1 that binds to both receptors. Ultimately, the choice between tirzepatide and semaglutide will depend on individual patient preferences and existing health conditions.

When a drug is in shortage, the FDA permits compounders to create a compounded version to meet demand. As of May 2023, both Ozempic and Wegovy are listed on the FDA's Drug Shortages list.

The time it takes to see significant weight loss can vary based on how long you've been on the medication and other factors. Most studies show notable results within 12 to 16 weeks, with patients typically losing about 5-10% of their initial body weight in the first three to six months. If your current medication isn’t working well for you, it's best to talk to your doctor. While it’s unclear if someone who doesn’t respond to one drug will respond to another, trying a second medication is often recommended.

GLP-1 products, or glucagon-like peptide-1 receptor agonists, are medications that help manage blood sugar levels and often promote weight loss. They work by increasing insulin production, which lowers blood sugar, and by reducing the amount of glucose produced by the liver.

The benefits of using GLP-1 products for weight loss include better blood sugar control, weight loss, and a lower risk of heart disease and stroke. Additionally, they can help reduce appetite and enhance feelings of fullness.

Side effects of GLP-1 products may include nausea, vomiting, diarrhea, and constipation, but these are typically mild and tend to improve over time.

GLP-1 products are usually administered via injection once a week. It's essential to follow your healthcare provider's instructions for proper use to achieve the best results.

Yes, GLP-1 products can be combined with other weight loss methods, such as diet and exercise. However, it's important to consult your healthcare provider to ensure that this approach is safe and effective for you.